NonAlcoholic Fatty Liver Disease (NAFLD)

What Is NAFLD?

NAFLD includes two main stages:

• Simple steatosis (nonalcoholic fatty liver NAFL): Fat accumulates in hepatocytes but inflammation and damage are minimal.
• Nonalcoholic steatohepatitis (NASH): Fat is accompanied by inflammation, ballooning degeneration of liver cells, and varying degrees of fibrosis. NASH can progress to cirrhosis and hepatocellular carcinoma.

When NAFLD occurs in children and adolescents, it is often called pediatric NAFLD, and it follows a similar pathophysiology.

How Common Is NAFLD?

Estimates suggest that 2530% of adults in many countries have NAFLD, and the prevalence is higher (up to 60%) among people with obesity, type 2 diabetes, or metabolic syndrome. The disease is also rising in younger populations, reflecting global trends in overweight and sedentary lifestyles.

Risk Factors & Causes

NAFLD is closely linked to metabolic dysfunction. The most important risk factors include:

• Obesity, especially central (visceral) adiposity
• Insulin resistance and type2 diabetes mellitus
• Dyslipidemia (high triglycerides, low HDLcholesterol)
• Hypertension
• Genetic predisposition (e.g., PNPLA3, TM6SF2 variants)
• Dietary factors high intake of fructose, saturated fats, and processed foods
• Sedentary lifestyle
• Polycystic ovary syndrome (PCOS)
• Certain medications (e.g., corticosteroids, amiodarone, some antiretrovirals)

While alcohol intake is minimal (<30g/day for men, <20g/day for women), other liverinjuring agents must be ruled out before diagnosing NAFLD.

Pathophysiology Why Fat Accumulates

NAFLD results from an imbalance between lipid acquisition and disposal in the liver. Key mechanisms include:

1. Increased free fatty acid (FFA) influx: Excess adipose tissue releases FFAs into the portal circulation.
2. Denovo lipogenesis: Hyperinsulinemia and high carbohydrate intake stimulate hepatic fattyacid synthesis.
3. Impaired betaoxidation: Mitochondrial dysfunction reduces the livers ability to burn fatty acids.
4. Reduced VLDL export: The livers capacity to package and secrete triglycerides as verylowdensity lipoprotein particles is overwhelmed.
5. Inflammatory & oxidative stress: Lipotoxic intermediates generate reactive oxygen species, leading to cellular injury and inflammation.

This multiplehit model explains why some individuals develop simple steatosis while others progress to NASH.

Signs & Symptoms

Early NAFLD is often silent. When symptoms appear, they may include:

• Fatigue or vague abdominal discomfort
• Rightupperquadrant dull ache
• Unexplained weight loss (more common in advanced disease)
• Enlarged liver on physical exam (hepatomegaly)

Advanced fibrosis or cirrhosis can cause jaundice, portal hypertension, ascites, or hepatic encephalopathy, but these findings occur late in the disease course.

Diagnostic Approach

Diagnosis combines clinical assessment, laboratory tests, imaging, and sometimes liver biopsy.

1. Laboratory Evaluation

• Elevated liver enzymes (ALT, AST) usually mild, ALT>AST.
• Increased glutamyl transpeptidase (GGT) and alkaline phosphatase.
• Metabolic panel fasting glucose, HbA1c, lipid profile.
• Exclusion of viral hepatitis, autoimmune liver disease, hemochromatosis, etc.

2. Imaging

• Ultrasound: Firstline; detects moderatetosevere steatosis but limited for fibrosis.
• Controlled attenuation parameter (CAP) with FibroScan: Quantifies fat and measures liver stiffness to estimate fibrosis.
• Magnetic resonance imagingbased techniques (MRIPDFF, MR elastography): Highly accurate for fat fraction and fibrosis.

3. Noninvasive Scoring Systems

Several calculators combine routine labs and clinical variables to estimate fibrosis risk:

• FIB4 Index
• NAFLD Fibrosis Score (NFS)
• ASTtoPlatelet Ratio Index (APRI)

4. Liver Biopsy

Considered the reference standard for distinguishing NAFL from NASH and grading fibrosis. Indications include:

• Uncertain diagnosis after noninvasive tests
• Rapidly rising liver enzymes
• Clinical suspicion of advanced fibrosis or cirrhosis

Because of its invasive nature, biopsy is reserved for selected patients.

Management & Treatment

There is no approved medication specifically for NAFLD, so therapy focuses on lifestyle modification and treatment of associated metabolic conditions.

1. Weight Reduction

Weight loss of 710% of body weight can:

• Decrease hepatic steatosis
• Improve insulin sensitivity
• Reduce inflammation and fibrosis in NASH

Approaches include calorierestricted diets, Mediterranean diet, or lowcarbohydrate diets, combined with regular physical activity (150minutes of moderate aerobic exercise per week).

2. Control of Metabolic Risk Factors

• Diabetes: Optimize glycemic control; GLP1 receptor agonists (e.g., liraglutide, semaglutide) have shown benefit in NASH.
• Lipid management: Statins are safe and recommended for dyslipidemia.
• Hypertension: Standard antihypertensive therapy.

3. Pharmacologic Options Under Investigation

Several agents are in clinical trials, including:

• FXR agonists (e.g., obeticholic acid)
• PPAR agonists (e.g., pioglitazone, lanifibranor)
• Antiinflammatory agents (e.g., cenicriviroc)
• Metabolic modulators (e.g., acetylCoA carboxylase inhibitors)

As of now, these drugs are not universally approved, and therapy should be individualized.

4. Monitoring

Followup schedule typically includes:

• Weight and waist circumference every 36months
• Liver enzymes annually (or more frequently if abnormal)
• Noninvasive fibrosis assessment (FibroScan or serum scores) every 12years in patients with advanced disease risk
• Screening for hepatocellular carcinoma (ultrasound AFP) in patients with cirrhosis

Complications

If untreated, NAFLD can lead to:

• Progressive fibrosis cirrhosis
• Portal hypertension and its sequelae (varices, ascites)
• Hepatocellular carcinoma, even in noncirrhotic livers
• Increased cardiovascular disease risk the leading cause of death in NAFLD patients

Prevention Strategies

Public health measures and individual actions that lower NAFLD incidence include:

• Promoting balanced nutrition rich in fruits, vegetables, whole grains, and healthy fats
• Limiting sugary beverages and excess fructose consumption
• Encouraging regular physical activity for all age groups
• Early detection and management of obesity, diabetes, and dyslipidemia
• Education campaigns about liver health in schools and workplaces

Key Takeaways

1. NAFLD is the most common chronic liver disease and is strongly linked to metabolic syndrome.
2. Simple steatosis can be benign, but about 2030% progress to NASH, which may evolve to cirrhosis.
3. Lifestyle changeespecially weight loss and increased activityremains the cornerstone of therapy.
4. Noninvasive fibrosis tests help identify patients needing closer surveillance.
5. Ongoing research promises targeted pharmacologic options, but they are not yet standard care.

Further Reading & Resources

• American Association for the Study of Liver Diseases (AASLD) aasld.org
• European Association for the Study of the Liver (EASL) easl.eu
• World Health Organization Noncommunicable diseases and liver health
• UpToDate: Nonalcoholic fatty liver disease in adults (subscription required)